![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication May 12, 2005.
Revised July 14, 2005.
Accepted for publication August 15, 2005.
Bisphenol A (BPA) is a weak estrogen. Pharmacokinetic studies of BPA have demonstrated a rapid and extensive metabolism of BPA to the non-estrogenic BPA-monoglucuronide (BPA-gluc). Some investigators have reported that BPA was found at parts per billion concentrations in the tissues or urine of humans without known exposure to BPA. This work developed a rapid and sensitive method for the determination of BPA and BPA-gluc in plasma and urine based on LC-MS/MS. The LC-ESI-MS/MS method for quantitation of BPA and BPA-gluc uses stable isotope labelled internal standards. A linear ion trap mass spectrometer permits identification and quantitation of BPA-gluc and BPA without sample workup. Development of separation conditions reduced the BPA-background in solvent samples to below 2.5 pmol/mL for BPA. Limit of quantitation (LOQ) for BPA in control urine was 15 pmol/mL, LOQ for BPA-gluc was 65 pmol/mL. Application of the method to urine samples from human subjects (n = 6) after administration of 25 µg BPA/person (estimated maximum human daily intake) permitted the determination of excretion kinetics for BPA-gluc; BPA was below the LOD in all except two of the samples. In urine or blood samples of human subjects (n = 19) without intentional exposure to BPA, BPA-concentrations were always below the limit of detection (
2.5 pmol/mL) with or without prior glucuronidase treatment.
The results show that care is required for analysis of BPA and its major metabolite BPA-gluc. The LOD obtained and the absence of detectable levels of BPA in samples from individuals suggests that general exposure of humans to BPA is much lower than worst-case exposure scenario developed.
Key words:
analytical chemistry, analytical pharmacology/toxicology, chemical toxicology, endocrine regulation, human pharmacokinetics, mass spectrometry, phase II drug metabolism, toxicology
This article has been cited by other articles:
![]() |
H. M. Koch and A. M. Calafat Human body burdens of chemicals used in plastic manufacture Phil Trans R Soc B, July 27, 2009; 364(1526): 2063 - 2078. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. N. Vandenberg, M. V. Maffini, C. Sonnenschein, B. S. Rubin, and A. M. Soto Bisphenol-A and the Great Divide: A Review of Controversies in the Field of Endocrine Disruption Endocr. Rev., February 1, 2009; 30(1): 75 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Kamrin The "Low Dose" Hypothesis: Validity and Implications for Human Risk International Journal of Toxicology, January 1, 2007; 26(1): 13 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. M. D. Schauer, W. Volkel, and W. Dekant Toxicokinetics of Tetrabromobisphenol A in Humans and Rats after Oral Administration Toxicol. Sci., May 1, 2006; 91(1): 49 - 58. [Abstract] [Full Text] [PDF] |
||||